Introduction
============

Since it was introduced in 1957, isolated limb perfusion has been an available therapeutic option for patients with locally advanced neoplasia, such as melanoma and sarcoma ([@b1-mco-0-0-1401],[@b2-mco-0-0-1401]). Isolation of the affected limb allows for the administration of high doses of chemotherapeutic agents, eliminating their associated severe systemic effects ([@b1-mco-0-0-1401],[@b2-mco-0-0-1401]). For this procedure, an extracorporeal circulation circuit is employed that incorporates a pump and an oxygenator to warm the perfusion solution and to enhance oxygen pressure prior to its administration ([@b3-mco-0-0-1401]). Melphalan and tumor necrosis factor α (TNFα), used either alone or in combination, are the cytotoxic agents of choice, and can be administered at doses ≥15--20 times the doses that are tolerated after systemic administration ([@b4-mco-0-0-1401]). A potential hazard that can occur during the procedure is the leaking of these agents into the systemic circulation ([@b5-mco-0-0-1401]). Nevertheless, the most common frequent adverse effects present locally, and consist of edema, erythema and unusual cases of neuropathy and vascular complications ([@b5-mco-0-0-1401]).

TNFα is a pleiotropic cytokine that is capable of destroying tumor neoangiogenic vessels ([@b6-mco-0-0-1401],[@b7-mco-0-0-1401]). Nevertheless, it is also involved in sepsis-induced cardiovascular dysfunction ([@b6-mco-0-0-1401],[@b7-mco-0-0-1401]). Systemic toxicity appears to be associated with the amount of leakage of these cytotoxic agents into the systemic circulation, and it is recommended that the procedure be stopped when this amount exceeds 10% ([@b8-mco-0-0-1401]). When it appears, systemic toxicity is usually limited, consisting of nausea and post-operative emesis, as well as transitory myelosuppression ([@b4-mco-0-0-1401]). However, due to the potential toxicity of these treatments, patients are often subject to invasive hemodynamic monitoring ([@b4-mco-0-0-1401]).

The aim of the present study was to investigate the incidence of organ dysfunction, and to describe the clinical characteristics and intensive care unit (ICU) outcomes of critically ill cancer patients who were admitted to an oncological ICU during the period following surgical isolated limb perfusion.

Patients and methods
====================

The present study was an observational and qualitative investigation of 42 critically ill cancer patients who were admitted to the ICU of the Instituto Nacional de Cancerología. All consecutive who were admitted to the ICU during the isolated limb perfusion post-operative period were included, between July 2010 and February 2016.

The chemotherapeutic agents used included TNFα and melphalan. Demographical, clinical and pathological data were collected from each patient on the first day following ICU admission, including the following: Location of the primary tumor; comorbidity; surgical duration; perioperative bleeding volume; crystalloid fluid volume required during the surgical procedure. In addition, during the initial 24 h of ICU admission, the following data were recorded: Complications (medical and surgical); mechanical ventilation and vasopressor therapy requirements and duration periods; ICU and hospital length of stay; ICU and hospital mortality rates due to any cause. Organ dysfunction was defined according to the Mexican Sequential Organ Failure Assessment (MEXSOFA) score as ≥1 point for any organ system ([@b9-mco-0-0-1401]).

Additionally, the Acute Physiology and Chronic Health Evaluation II and MEXSOFA scores were calculated using the poorest acute physiological variable values obtained during the first 24 h of ICU admission ([@b10-mco-0-0-1401]). Systemic inflammatory response syndrome was defined as two or more of the following: i) Temperature \>38°C or \<36°C; ii) heart rate \>90/min; iii) respiratory rate \>20/min or PaCO~2~ \<32 mm Hg (4.3 kPa); iv) white blood cell count \>12,000/mm^3^ or \<4,000/mm^3^ or \>10% immature bands ([@b11-mco-0-0-1401]). Subsequently, the patients were divided into two groups according to the number of organ system dysfunctions (≤1 organ dysfunction, n=21; ≥2 organ dysfunctions, n=21). The patients were followed-up for one year after discharge from the ICU. Patients were considered lost to follow-up if they had not visited the hospital for 90 days. The Bioethics Committee of The Instituto Nacional de Cancerología approved the present study, and the requirement to obtain informed consent was waived.

Statistical analysis. Categorical data are expressed as percentages. Continuous variables are expressed as the mean ± standard deviation. All continuous variables were analyzed for normality using the Kolmogorov-Smirnoff test and compared by performing a Student\'s t-test. All statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). Two-sided P\<0.05 values were considered to indicate a statistically significant difference.

Results
=======

The mean age of the patients was 45.7±16.9 years, and 45.2% (19 cases) were female. Soft tissue sarcoma was the most common pre-operative diagnosis (38.1%), and the mean duration of surgery was 267.6±50.1 min. Furthermore, a mean blood loss volume of 732.3±526.1 ml was recorded during the procedure; the patients received a mean peri-operative volume of 3.88±1.28 liters crystalloid fluid and required an additional 2.95±6.28 liters on the first post-operative day ([Table I](#tI-mco-0-0-1401){ref-type="table"}).

During the initial 24 h following admission to the ICU, four patients required vasopressors (9.5%) and two patients required invasive mechanical ventilation (4.7%) for a mean duration of one day. Furthermore, 21.4% of the patients exhibited systemic inflammatory response syndrome.

Overall, 23 patients (54%) required packed red blood cell transfusions. Additionally, the incidence of organ dysfunction was 90.5% and was most frequently noted in the respiratory (81%), hepatic (33%), hematologic (31%) and renal (11.9%) systems ([Table II](#tII-mco-0-0-1401){ref-type="table"}). Five of the patients (11.9%) exhibited renal dysfunction; however, no patients required or received renal replacement therapy. During the ICU and hospital stay, no patients were recorded as having succumbed to the disease. After one year of follow-up, all patients remained alive. In total, 4.7% of patients (2/42) were lost to follow-up, according to the aforementioned criterion.

Discussion
==========

Isolated limb perfusion using TNFα has previously been associated with major systemic changes that are characterized by a septic-like shock syndrome ([@b12-mco-0-0-1401],[@b13-mco-0-0-1401]). In the current study, the incidence of organ dysfunction was 90.5% in critically ill cancer patients who were admitted to the ICU during the isolated limb perfusion post-operative period, being most frequently noted in the respiratory, hepatic and coagulation systems.

Laurenzi *et al* ([@b14-mco-0-0-1401]) reported that 17% of observed critically ill patients developed severe respiratory and cardiovascular toxicity; of these patients, all required mechanical ventilation and 11% required vasoactive treatment ([@b14-mco-0-0-1401]). In the present study, \<10% of the patients required vasopressors and \<5% required invasive mechanical ventilation. All patients were extubated during the first day on the ICU.

In contrast to prior studies, the current study did not report the volume of drug leakage from the limb to the systemic circulation, which is reportedly correlated with the degree of systemic toxicity ([@b8-mco-0-0-1401],[@b15-mco-0-0-1401]). It is notable that isolated limb perfusion is stopped when the leakage from the limb to the systemic circulation reaches 5% when using TNFα, or 10% when using melphalan in the Instituto Nacional de Cancerología.

The primary limitations of the present study were that it represented the experience of a single oncological ICU and that the sample size was small.

In conclusion, a high incidence of organ dysfunction was observed. Nevertheless, \<5% of the patients required invasive mechanical ventilation and \<10% required vasopressors. Therefore, ICU admission directly following isolated limb perfusion should not be standardized.

The present authors thank the ICU nurses and medical staff of the Instituto Nacional de Cancerología who were involved in the care of the study patients. The present study was supported by institutional funds.

###### 

Patient demographic and clinical data

  Characteristics                                                                    Values
  ---------------------------------------------------------------------------------- -------------
  Total patients, n (%)                                                              42 (100)
  Age, years^[a](#tfn1-mco-0-0-1401){ref-type="table-fn"}^                           45.7±16.9
  Sex, n (%)                                                                         
    Female                                                                           19 (45.2)
    Male                                                                             23 (54.8)
  APACHE II score^[a](#tfn1-mco-0-0-1401){ref-type="table-fn"}^                      9.1±3.3
  MEXSOFA score^[b](#tfn2-mco-0-0-1401){ref-type="table-fn"}^                        3 (2--4)
  Diagnosis, n (%)                                                                   
    Sarcoma                                                                          16 (38.1)
    Liposarcoma                                                                      8 (19)
    Melanoma                                                                         7 (16.7)
    Fibromatosis                                                                     5 (11.9)
    Squamous cell carcinoma                                                          2 (4.8)
    Neurogenic sarcoma                                                               1 (2.4)
    Myxofibrosarcoma                                                                 1 (2.4)
    Fibroblastoma                                                                    1 (2.4)
    Merkel cell carcinoma                                                            1 (2.4)
  Duration of surgery, min^[a](#tfn1-mco-0-0-1401){ref-type="table-fn"}^             267.6±50.1
  TNFα administration, n (%)                                                         37 (88)
  Perioperative bleeding, ml^[a](#tfn1-mco-0-0-1401){ref-type="table-fn"}^           732.3±526.1
  Vasopressors, n (%)                                                                4 (9.5)
  Invasive mechanical ventilation, n (%)                                             2 (4.7)
  Crystalloid fluid received, liters^[a](#tfn1-mco-0-0-1401){ref-type="table-fn"}^   
    During surgery                                                                   3.88±1.28
    Following admission to the ICU                                                   2.95±6.28
  Length of stay in the ICU, days^[a](#tfn1-mco-0-0-1401){ref-type="table-fn"}^      1 (0--1)

Data are presented as the mean ± standard deviation.

Data are presented as the median (interquartile range). APACHE, acute physiology and chronic health evaluation; MEXSOFA, Mexican sequential organ failure assessment; TNFα, tumor necrosis factor α; ICU, intensive care unit.

###### 

Patients according to the number of dysfunctional organ systems.

                                                                              Organ dysfunction                       
  --------------------------------------------------------------------------- ------------------- ------------------- -------------------------------------------------------
  Hemoglobin, g/l^[a](#tfn3-mco-0-0-1401){ref-type="table-fn"}^               10.39±1.4           10.07±1.67          0.513
  Platelets, ×10^9^/l^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^           189 (174--233)      138 (120--157)      \<0.001^[c](#tfn5-mco-0-0-1401){ref-type="table-fn"}^
  White blood cells, ×10^9^/l^[a](#tfn3-mco-0-0-1401){ref-type="table-fn"}^   17.9±5.9            17.1±4.3            0.735
  Creatinine, mg/dl^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^             0.65 (0.61--0.84)   0.78 (0.63--0.99)   0.217
  Albumin, mg/dl^[a](#tfn3-mco-0-0-1401){ref-type="table-fn"}^                2.49±0.39           2.49±0.65           0.980
  Total bilirubin, mg/dl^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^        0.9 (0.7--1.2)      1.2 (1.0--1.7)      0.032^[c](#tfn5-mco-0-0-1401){ref-type="table-fn"}^
  pH^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^                            7.31 (7.30--7.37)   7.32 (7.30--7.37)   0.800
  Bicarbonate, mEq/l^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^            19.7 (18.0--22.1)   20.0 (19.0--21)     0.504
  Lactate, mmol/l^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^               2.4 (2.18--3.2)     2.4 (1.3--2-6)      0.231
  Sodium, mEq/l^[a](#tfn3-mco-0-0-1401){ref-type="table-fn"}^                 137.4±2.39          138.3±2.7           0.264
  Potassium, mEq/l^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^              3.9 (3.7--4.0)      3.8 (3.6--4.2)      0.604
  Chloride, mEq/l^[a](#tfn3-mco-0-0-1401){ref-type="table-fn"}^               110.4±3.8           112.3±3.8           0.129
  Calcium, mg/dl^[a](#tfn3-mco-0-0-1401){ref-type="table-fn"}^                7.31±0.49           6.85±1.58           0.307
  Phosphorus, mg/dl^[b](#tfn4-mco-0-0-1401){ref-type="table-fn"}^             3.3 (3.1--3.6)      3.1 (2.8--3.9)      0.571
  Magnesium, mEq/l^[a](#tfn3-mco-0-0-1401){ref-type="table-fn"}^              1.62±0.46           1.59±0.28           0.828

Data presented as the mean ± standard deviation.

Data presented as the median (interquartile range).

P\<0.05. ICU, intensive care unit.
